Hyderabad, India-headquartered Aurobindo Pharma announced that its wholly- owned subsidiary Eugia Pharma Specialties, received final approval from the U.S. Food & Drug Administration to manufacture and market Leuprolide Acetate injection, 14 mg/2.8 mL MDV (Kit). This drug is indicated for the palliative treatment of advanced prostate cancer. The product is...